GLP‑1 weight‑loss pill OK'd
The FDA has approved oral semaglutide as the first GLP‑1 pill for weight loss, offering a non‑injectable option for people with obesity or overweight. (AJMC: FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss) The approval comes as telehealth access is expanding—Cora Health says it now offers GLP‑1 appointments across 44 states—and industry groups note pharmacy benefit managers are already using cost‑management and support services to widen access. (Cora Health expansion: ) (PBM access: )
A class of obesity drugs that mimics a gut hormone to curb appetite now includes a daily pill, not just weekly shots. The Food and Drug Administration approved Wegovy tablets, an oral semaglutide form, for long-term weight management in adults in December 2025. (accessdata.fda.gov) The label says the tablets are for adults with obesity, or adults who are overweight and have at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The same oral product is also cleared to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. (accessdata.fda.gov) This is not the same as taking any semaglutide pill. Wegovy tablets are a weight-management product, while oral semaglutide had already been on the market for type 2 diabetes as Rybelsus. (fda.gov) The new pill comes with handling rules that do not apply to the injection. Patients are told to take one tablet once daily in the morning on an empty stomach with up to 4 ounces of water and wait at least 30 minutes before eating, drinking, or taking other medicines. (accessdata.fda.gov) Novo Nordisk said on December 22, 2025 that the pill was the first oral glucagon-like peptide-1 medicine for obesity in the United States and pointed to a mean weight loss of 16.6% in the OASIS 4 trial. The Food and Drug Administration label lists a 25 milligram tablet formulation for Wegovy. (nasdaq.com) (accessdata.fda.gov) The market shifted again last week when Eli Lilly won Food and Drug Administration approval for Foundayo, its oral glucagon-like peptide-1 drug orforglipron, for obesity. Managed Healthcare Executive reported that the approval set up direct competition with the semaglutide Wegovy pill approved in December 2025. (managedhealthcareexecutive.com) Access is widening through channels beyond the doctor’s office. Cora Health said on April 13, 2026 that it now offers provider-guided compounded semaglutide and tirzepatide appointments in 44 states, with plans starting at $120 a month and medications shipped from a United States-licensed compounding pharmacy. (markets.financialcontent.com) Cora Health also said compounded drugs are not Food and Drug Administration-approved and are not therapeutically equivalent to approved products. That distinction matters as branded pills and shots expand while telehealth sellers continue to market lower-cost compounded versions. (markets.financialcontent.com) Insurers and pharmacy benefit managers are building new controls around the category at the same time. The Pharmaceutical Care Management Association said on April 13, 2026 that many pharmacy benefit managers now pair coverage with coaching, nutrition support, digital tracking tools, and behavior-change programs intended to improve adherence and manage employer costs. (pcmanet.org) Federal policy is moving in the same direction. The Centers for Medicare and Medicaid Services said on March 9, 2026 that participating state Medicaid agencies could begin a new BALANCE model as early as May 2026, with a Medicare Part D bridge program starting in July 2026 to expand access to select weight-management glucagon-like peptide-1 drugs. (cms.gov) The result is a more crowded obesity-drug market than patients faced a year ago: a daily semaglutide pill with strict dosing instructions, a newly approved rival pill from Eli Lilly, and a fast-growing telehealth and benefit-management system deciding who gets which version and at what price. (accessdata.fda.gov) (managedhealthcareexecutive.com) (cms.gov)
